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ABSTRAK
Latar belakang: kanker serviks menduduki peringkat ke tiga di seluruh dunia sebagai penyebab kematian 
perempuan dan merupakan penyebab kematian utama perempuan di negara berkembang. Diperlukan evaluasi 
kesintasan berkala yang secara tidak langsung menjadi cermin tatalaksana. Penelitian ini bertujuan mengetahui 
kesintasan pasien kanker serviks di Rumah Sakit Cipto Mangunkusumo sebagai rumah sakit rujukan nasional 
di Indonesia. Metode: penelitian ini menggunakan desian kohort retrospektif terhadap data rekam medis pasien 
kanker serviks pada tahun 2012-2014 dengan metode total population sampling. Analisis data dilakukan 
menggunakan kurva Kaplan Meier, uji Log Rank dan Regresi Cox untuk mencari kemaknaan hubungan 
antarvariabel. Hasil: terdapat 1,303 subjek penelitian dengan angka kesintasan kanker serviks hingga tahun 
ke-5 sebesar 76%, 65%, 59%, 43% dan 34% dengan median kesintasan sebesar 1,316 hari secara keseluruhan. 
Terdapat perbedaan hazard bermakna pada variabel stadium kanker (p<0.001). Analisis regresi cox menunjukkan 
faktor yang berpengaruh terhadap kesintasan adalah stadium kanker. Kesimpulan: kesintasan 5 tahun kanker 
serviks di RSCM tahun 2012-2014 sebesar 34%.
Kata kunci: kanker serviks, kesintasan, rumah sakit nasional.
ABSTRACT
Background: cervical cancer is the third leading cause of female deaths worldwide, and it is the leading 
cause of female deaths in developing countries. A routine survival evaluation is required to imply the result 
of the treatment. The aim of this study was to determine the cervical cancer patient survival rate at the Cipto 
Mangunkusumo hospital as national referral hospital in Indonesia. Methods: our retrospective cohort study 
utilized the medical records of cervical cancer patients from 2012 to 2014 using total population sampling 
method. The data analysis was conducted using the Kaplan-Meier curve, log rank test and Cox regression to 
determine significant associations between variables. Results: there were 1,303 subjects with overall survival 
rates of cervical cancer up to the fifth year of 76%, 65%, 59%, 43% and 34%, respectively, with a median 
survival of 1,316 days. There were significant differences of hazard ratio for cancer stage variables (p<0.001), 
and the Cox regression analysis showed that the factor affecting survival was  cancer stage. Conclusion: the 
5-year cervical cancer survival rate at the Cipto Mangunkusumo hospital from 2012 to 2014 was 34%.
Keywords: cervical cancer, survival rate, national hospital.
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INTRODUCTION
Cervical cancer is one of the most common 
malignancies worldwide. Globally, it is the third 
leading cause of female deaths and the seventh 
leading cause of death in the total population. 
Moreover, it is the leading cause of female deaths 
in developing countries. According to the Global 
Cancer Incidence, Mortality and Prevalence 
database, there were 530,000 new cervical 
cancer cases in 2008, with more than 85% of 
these occurring in developing countries. Overall, 
cervical cancer causes 275,000 deaths annually 
and the cervical cancer mortality in Indonesia 
reached 7,493 deaths in 2008.1
However, there are discrepancies in the 
cervical cancer 5-year survival rates among 
countries. In a study by Sankaranarayanan et al. 
conducted from 1990 to 2000, various survival 
rates were reported: 46.4% in India, 65.7% in 
Singapore, 37.4% in the Philippines, 63.5% 
in China, 79.5% in Hong Kong and 54% in 
Thailand. In European countries, the survival 
rates were 59.1% in the United Kingdom, 64% 
in Denmark, 63.7% in Austria, 51.5% in Poland, 
65% in Belgium and 60.5% in Germany.2
In Indonesia, a study was conducted at the 
Cipto Mangunkusumo Hospital in Jakarta in 
1997. During the 5-year follow up, 47.9% of 
the subjects died, 14.6% survived and 37.6% 
dropped out.3 The 5-year survival rate in that 
study was 30.3%, with a median survival of 
934 days. Another study in 2001 examined the 
survival rate among patients grouped according 
to their cancer stages. The 5-year survival rates 
of the patients with cervical cancer stages I, 
II, III and IV were 50%, 40%, 20% and 0%, 
respectively.3 A study in another Indonesian 
hospital in 1996 reported a 40.3% 5-year survival 
rate. The grouping based on the cancer stages 
revealed that the survival rates were 56.6% for 
stage I, 56.0% for stage II, 23.7% for stage III 
and 0 for stage IV. The study also examined 
different therapies received by the patients. Those 
who were treated with surgery alone had a 35% 
survival rate, with a median survival of 1,236 
days; while those treated with radiation had a 
38% survival rate, with a median survival of 
1,127 days. The patients who were treated with 
chemotherapy had a median survival of 273 days. 
Among the patients receiving combined therapy, 
those who underwent surgery and chemotherapy 
had a median survival of 123 days, those who 
underwent surgery and radiation had a 61% 
survival rate, with a median survival rate of over 
50%, and those who were treated with radiation 
and chemotherapy had a median survival of 509 
days.4
A paper published by Andrae et al. reported 
567 cervical cancer cases in Sweden between 
1999 and 2001. They found that the stage IA 
cases had a survival rate of 94%, the stage IB 
cases had a survival rate of 81% and the stage 
IA or higher cases had a 40% survival rate. They 
also examined the survival rate based on cancer 
histopathology and  found the following results: 
the survival rate among patients with squamous 
cell carcinoma was 71%, the rate for patients 
with adenocarcinoma was 68%, for those with 
adenosquamous carcinoma, it was 73% and for 
those with small cell carcinoma, it was 44%.5 In 
a study conducted in Bologna, Italy, Syrjanen et 
al. reported that the median survival among the 
patients with squamous cell carcinoma was 13 
months in those cases with tumour sizes larger 
than 2 cm, and it was 37 months in those cases 
with tumour sizes of less than 2 cm.6
With regard to cervical cancer, there has 
been a consistent decline in the mortality rate 
over the last 40 years and a consistent rise in the 
5-year survival rate due to the introduction of 
screening programs in many countries.7 The most 
important prognostic factors include the cancer 
stage, tissue histopathology, screening history, 
degree of tissue differentiation, metastasis and 
response to therapy.3,5 However, there have not 
been adequate studies addressing the cervical 
cancer survival rate based on histopathology and 
response to therapy. Reliable data regarding these 
prognostic factors may be essential for clinicians 
to determine and evaluate the treatment options 
for their cervical cancer patients. The aim of 
this study was to determine the cervical cancer 
patient survival rate at the Cipto Mangunkusumo 
hospital as national referral hospital in Indonesia 
METHODS
Our study was a retrospective cohort study. 
Data was collected from the medical records of 
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cervical cancer patients at Cipto Mangunkusumo 
Hospital from 1 January 2012 to 31 December 
2014. The inclusion criteria were patients in 
the OBGYN Oncology Division who were 
diagnosed during the aforementioned duration of 
study with reliable medical records. No exclusion 
criteria were set for this study. This study has 
been approved by the Ethics Committee of 
Faculty of Medicine Universitas Indonesia, 
reference number 655/UN2.F1/ETIK/2017.
Data collected in this study were age, 
parity children, marriage age, FIGO staging, 
histopathology, type of treatment, and outcome 
(die or alive). The total number of samples 
needed was 249 subjects. The subjects were 
enrolled in this study using a consecutive 
sampling technique. Data collection and 
input were conducted by trained physicians 
and medical students. Statistical analysis was 
conducted using Stata 10 (StataCorp LLC, 
College Station, TX, USA) and data analysis 
was performed using the Kaplan-Meier curve, 
log-rank test and Cox regression to determine 
the associations between variables.
RESULTS
A total of 1,651 patients with cervical cancer 
were found in the registry between 2012 and 
2014. Data validation was conducted for all of 
necessary variables and this resulted in 1,303 
valid subjects. Any missing data were completed 
using the imputation method. With regard to the 
missing data, 3 subjects had missing age data, 
236 had missing marriage age data, 250 had 
missing cancer staging data, 208 had missing 
tissue histopathology data, 452 had missing 
treatment option data and 169 had missing 
outcome data. There were 368 (28.2%) deaths 
that were counted as events. Of the 1,303 cervical 
cancer patients included in this study, the mean 
age was 53 years old, the youngest was 27 
years old, and the oldest was 87 years old. The 
demographic characteristics of all of the subjects 
are presented in Table 1.
There were 1,303 subjects with overall 
survival rates of cervical cancer up to the 
fifth year of 76%, 65%, 59%, 43% and 34%, 
respectively, with a median survival of 1,316 
days. An analysis was performed to compare 
Table 1. Demographic and clinical characteristics of the 
study subjects
Variables Value (n = 1,303)
Age (years), Mean (SD) 53.18 (9.5)
Parity [children, n (%)]
 - Nulliparous 135 (10.4)
 - Primiparous 90 (6.9)
 - Multiparous 921 (7.7)
 - Grand multiparous 157 (12.0)
Marriage age [years, n (%)]
 - < 20 years old 882 (67.7)
 - 20 – 30 years old 402 (30.8)
 - > 30 years old 19 (1.5)
FIGO staging [n (%)]
 - Stage I 137 (10.5)
 - Stage II 335 (25.7)
 - Stage III 707 (54.3)
 - Stage IV 124 (9.5)
Histopathology [n (%)]
 - Squamous cell carcinoma 1009 (77.4)
 - Adenocarcinoma 172 (13.2)
 - Adenosquamous 122 (9.4)
Treatment [n (%)]
 - Surgery 48 (3.7)
 - Surgery + chemotherapy 19 (1.5)
 - Surgery + radiation 90 (6.9)
 - Radiation 867 (66.5)
 - Chemotherapy 39 (3.0)
 - Radiation + chemotherapy 240 (18.4)
Outcome [n (%)]
 - Die 368(28.2)
 - Live 935 (71.8)
SD: standard deviation; FIGO: International Federation 
of Gynaecology and Obstetrics
survival rates of the subjects grouped by their 
demographic and clinical characteristics. 
However, in the further bivariate analysis 
using the log rank Cox regression, we found 
no significant difference in the survival rates 
of the subjects when they were grouped by age 
(p=0.59), parity (p=0.75), duration of marriage 
(p=0.92), tissue histopathology (p=0.16) and 
treatment (p=0.65).
 The only variable associated with a significant 
survival rate difference was the cancer staging 
(p<0.005). Based on cancer staging of our 
subjects, we found that the median survival time 
for patients with stages II, III and IV were 1,900 
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days, 1,243 days and 328 days, respectively. The 
survival rates for these subjects were 58% (stage 
I), 76% (stage II), 23% (stage III) and 0 (stage 
IV). The median survival is shown in the Kaplan-









Figure 1. Kaplan-Meier survival curve classified by cancer 
staging.
The bivariate analysis with reference to stage 
I revealed that patients with stage III cervical 
cancer had a hazard ratio (HR) of 1.68 [95% 
confidence interval (CI): 1.05–2.68] and those 
with stage IV cervical cancer had an HR of 3.93 
(95% CI: 2.39–6.47). The complete results of the 
bivariate analysis are shown in Table 2.
We performed further analysis using 
multivariate Cox regression to determine the 
effects of certain variables in relation to others. 
The variables with p values of less than 0.25 in 
the bivariate analyses, those that did not satisfy 
the proportional hazard assumption and those 
that were theoretically important were included. 
The variables that fulfilled these criteria were 
parity (primiparous), cancer staging (stages I, 
II, III and IV), adenocarcinoma and surgery + 
radiation. The results of the multivariate analysis 
are shown in Table 3.
The multivariate analysis showed that only 
cancer stages III and IV significantly affected the 
5-year survival rates of cervical cancer patients 
with adjusted HRs of 1.68 (95% CI: 1.05–2.68) 
and 3.93 (95% CI: 2,39 – 6.47), respectively. 
However, based on our clinical judgment, several 
other variables, such as the age, histopathology 
Table 2. Cox regression bivariate analysis of the 5-year 
cervical cancer survival rate.
Variables HR 95% CI
Age (Ref. 0 – 30 years)
 - 30 – 50 1.877 0.259 – 13.587
 - > 50 1.814 0.251 – 13.101
Parity (Ref. Nulliparous)
 - Primiparous* 1.402 0.836 – 2.351
 - Multiparous 0.992 0.676 – 1.457
 - Grand multiparous 0.837 0.516 – 1.356
Marriage age (Ref. <20 years old)
 - 20 – 30 years old 1.877 0.259 – 13.587
 - > 30 years old 1.814 0.251 – 13.108
Staging** (Ref. I)
 - II 0.700 0.418 – 1.171
 - III** 1.681 1.053 – 2.684
 - IV** 3.936 2.392 – 6.475
Histopathology* (Ref. Squamous cell carcinoma)
 - Adenocarcinoma* 0.773 0.542 – 1.101
 - Adenosquamous 
carcinoma 1.041 0.726 – 1.493
Treatment (Ref. Surgery)
 - Surgery + 
chemotherapy 0.860 0.309 – 2.387
 - Surgery + radiation* 0.626 0.285 – 1.374
 - Radiation 1.079 0.549 – 2.119
 - Chemotherapy 0.934 0.385 – 2.268
 - Radiation + 
chemotherapy 0.868 0.425 – 1.773
HR: hazard ratio, CI: confidence interval; *p value of 
less than 0.25; **p value of less than 0.05.
Table 3. Cox regression multivariate analysis of the 
5-year cervical cancer survival rate.
Variables Adjusted HR 95% CI on the HR
Staging (Ref. I)
 - II 0.700 0.418 – 1.171
 - III 1.681 1.053 – 2.684
 - IV 3.936 2.392 – 6.475
CI: confidence interval, HR: hazard ratio
and therapy were also essential for predicting 
patient survival rates.
DISCUSSION
The demographic characteristics of our 
study subjects are not much different from those 
of the study conducted by Sirait et al6 at the 
Dharmais Cancer Hospital in Jakarta in 2003. 
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In their study, the mean age was 50 years old, 
with the youngest patient was 21 years old and 
the oldest was 80 years old. However, the results 
of our study are different when compared to a 
previous study that was conducted at the Cipto 
Mangunkusumo Hospital by Nuranna et al.8 in 
2012, which reported a mean age of 47.5 years 
old, with the youngest patient was 24 years old 
and the oldest was 73 years old. In general, the 
age characteristic of our study subjects was 
older than those of the other studies.9 According 
to the 2001–2009 National Cancer Institute 
Surveillance, Epidemiology and End Result 
report, the average age of cervical cancer patients 
was 49 years old with 62% of them under 55 
years old and 38% of them over 55 years old.10
Our results showed that the overall 5-year 
survival rate was 34%, with a median survival 
of 1,316 days. The number was lower than that 
in the 2012 study conducted by Nuranna et al. 
that found a 5-year survival rate of 52%, with a 
median survival of 1,916 days, and it was only 
slightly higher than the results reported by Sirait 
et al.9 in 1997 that found  30% survival rate and a 
median survival of 934 days. All of these studies 
were conducted in Jakarta, and the results were 
lower than those in a report released by FIGO 
in 2006.5 The survival rate for that large study, 
which included 11,775 subjects, was 69.6%. The 
discrepancy in the results may have been caused 
by the fewer subjects with early cancer stages.
Based on the staging diagnosis, the median 
of survival in our study were consistent with 
previous results regarding the overall analysis; 
our findings were lower than those reported by 
Nuranna et al.8, but they are slightly better than 
those reported by Sirait et al.9 It is important to 
note that these findings may have been caused by 
the higher proportion of subjects who had more 
advanced clinical stages.
There was no survival difference between 
the subjects with stage I cervical cancer and 
those with stage II cervical cancer.8 In our 
study, there was no significant relationship 
between the histopathology and the cervical 
cancer survival rate (p>0.05). However, based 
on the hazard ratios, it was determined that 
adenocarcinoma (HR=0.73) was more protective 
than squamous cell carcinoma (HR=1.00); 
moreover, adenosquamous carcinoma (HR=1.04) 
did not differ significantly from squamous cell 
carcinoma in relation to the survival. Regarding 
the histopathological survival reported by 
Nuranna et al.8, patients with squamous cell 
carcinoma had worse prognosis, followed by 
adenosquamous carcinoma and adenocarcinoma. 
In one previous study involving 703 hospitals 
with a total of 11,157 cases, there was no 
significant difference in the 5-year survival 
among patients with squamous cell carcinoma, 
adenocarcinoma and adenosquamous carcinoma, 
except with regard to metastases to lymph 
nodes.11
CONCLUSION
Our study shows that the 5-year cervical 
cancer patient survival rate at the Cipto 
Mangunkusumo Hospital in Jakarta from 2012 
to 2014 was 34%, and it was significantly 
affected by the cancer staging at the time of the 
diagnosis. Subjects with stage III and stage IV 
cervical cancer had lower chances of survival 
(adjusted HRs: 1.68 and 3.93, respectively) when 
compared to those with stage I cancer.
Our study was conducted for a longer 
duration and it involved a larger sample size than 
the prior studies conducted in a similar setting. 
Our results also offered data on a prediction of 
the disease outcome and its clinical progression. 
However, we are aware that a retrospective cohort 
design is highly prone to informational bias in 
the data collection, and there were difficulties 
accessing certain medical records, which resulted 
in numerous incidences of incomplete data.
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